# STX6

## Overview
STX6 is a gene that encodes the protein syntaxin 6, a member of the SNARE (Soluble NSF Attachment Protein Receptor) family, which is integral to intracellular membrane trafficking. Syntaxin 6 is primarily involved in the transport processes within the trans-Golgi network and endosomal compartments, playing a crucial role in vesicle fusion and protein sorting. This protein is essential for maintaining cellular homeostasis and is implicated in various physiological processes, including immune cell exocytosis and the degradation of specific proteins such as the cystic fibrosis transmembrane conductance regulator (CFTR) (Wendler2001Syntaxin; Sangar2022Syntaxin6). Alterations in STX6 expression have been linked to several pathological conditions, including cancer and neurodegenerative diseases, underscoring its significance in both health and disease (Zhang2022Role; Du2016Essential).

## Function
Syntaxin 6 (STX6) is a SNARE protein that plays a critical role in intracellular membrane transport processes, particularly within the trans-Golgi network (TGN) and endosomal compartments. It is involved in various membrane-trafficking events, including the recycling of cargo between the TGN and early endosomes, and is essential for maintaining cellular homeostasis (Wendler2001Syntaxin; Sangar2022Syntaxin6). STX6 is part of the t-SNARE complex, which facilitates the fusion of vesicles with target membranes, a process crucial for protein sorting and membrane fusion (Sangar2022Syntaxin6).

In healthy human cells, STX6 is implicated in the transport of cholera toxin B from early endosomes to the Golgi complex, highlighting its role in specific endosome-to-Golgi transport pathways (Ganley2008A). It also plays a role in the degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) by promoting its lysosomal degradation, a process that involves interaction with the CFTR-associated ligand (CAL) (Cheng2010Syntaxin). STX6 is also involved in immune cell exocytosis, promoting the secretion and transport of TNF-α in activated macrophages and mediating the release of neutrophil inflammatory granules (Huang2024Syntaxin6).

## Clinical Significance
Alterations in the expression of the STX6 gene have been implicated in several diseases, including various cancers and neurodegenerative disorders. In esophageal squamous cell carcinoma (ESCC), STX6 expression is significantly higher in tumor tissues compared to adjacent non-tumor tissues. This overexpression correlates with tumor size, histological differentiation, lymph node metastasis, and tumor depth, suggesting that STX6 may drive ESCC progression. Knocking down STX6 in ESCC cell lines results in reduced cell proliferation and increased p53 expression, indicating a p53-dependent mechanism for growth suppression (Du2016Essential).

In hepatocellular carcinoma (HCC), STX6 is upregulated and associated with poor prognosis. High STX6 expression correlates with larger tumor size, higher Edmondson grade, and increased alpha-fetoprotein levels. It is also linked to immune cell infiltration, particularly M2 macrophages, suggesting a role in immunosuppression and tumor progression (Zhang2022Role).

STX6 is also implicated in neurodegenerative diseases. A genome-wide association study identified risk variants in STX6 associated with sporadic Creutzfeldt-Jakob disease (sCJD). Increased STX6 expression in specific brain regions may elevate the risk of sCJD, highlighting its potential role in the disease process (Jones2020Genomewide).

## Interactions
Syntaxin 6 (STX6) is a SNARE protein involved in intracellular trafficking and membrane fusion processes. It interacts with several proteins to facilitate these functions. STX6 is known to interact with the cystic fibrosis transmembrane conductance regulator (CFTR) and the CFTR-associated ligand (CAL). This interaction is crucial for directing CFTR towards lysosomal degradation. STX6 binds to the N-terminal half of CFTR, while CAL binds to the C-terminus, facilitating CFTR's lysosomal degradation (Cheng2010Syntaxin).

In the context of cancer, STX6 interacts with the receptor for activated protein kinase C (RACK1) in hepatocellular carcinoma (HCC). This interaction recruits STAT3, forming a protein-binding complex that enhances STAT3 transcriptional activity, promoting tumor progression through the JAK-STAT signaling pathway (Huang2024Syntaxin6).

STX6 is also involved in integrin trafficking, which is essential for cell migration. This role is particularly noted in esophageal squamous cell carcinoma (ESCC), where STX6's interaction with integrins affects cell viability and proliferation (Du2016Essential). These interactions highlight STX6's role in both physiological and pathological processes.


## References


1. (Jones2020Genomewide) Genome-wide association study identifies risk variants for sporadic Creutzfeldt-Jakob disease in STX6 and GAL3ST1. This article has 0 citations.

2. (Sangar2022Syntaxin6) Syntaxin-6 delays prion protein fibril formation and prolongs presence of toxic aggregation intermediates. This article has 3 citations.

[3. (Huang2024Syntaxin6) Li Huang, Xiaoting Zhong, An Li, Fuping Tu, Miao He, Xueming Xu, Xiaohui Liu, Xiaoli Zeng, Jun Chi, Tian Tian, Chunli Wang, Xiangcai Wang, and Jianming Ye. Syntaxin6 contributes to hepatocellular carcinoma tumorigenesis via enhancing stat3 phosphorylation. Cancer Cell International, June 2024. URL: http://dx.doi.org/10.1186/s12935-024-03377-3, doi:10.1186/s12935-024-03377-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-024-03377-3)

[4. (Zhang2022Role) Yang Zhang, Leyan Li, Yi Tu, Zongfeng Feng, Yong Li, and Jianbo Xiong. Role of stx6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma. Oncology Letters, September 2022. URL: http://dx.doi.org/10.3892/ol.2022.13491, doi:10.3892/ol.2022.13491. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2022.13491)

[5. (Ganley2008A) Ian G. Ganley, Eric Espinosa, and Suzanne R. Pfeffer. A syntaxin 10–snare complex distinguishes two distinct transport routes from endosomes to the trans-golgi in human cells. The Journal of Cell Biology, 180(1):159–172, January 2008. URL: http://dx.doi.org/10.1083/jcb.200707136, doi:10.1083/jcb.200707136. This article has 141 citations.](https://doi.org/10.1083/jcb.200707136)

[6. (Du2016Essential) Jin Du, Xiang Liu, Yanhu Wu, Jinfu Zhu, and Yihu Tang. Essential role of stx6 in esophageal squamous cell carcinoma growth and migration. Biochemical and Biophysical Research Communications, 472(1):60–67, March 2016. URL: http://dx.doi.org/10.1016/j.bbrc.2016.02.061, doi:10.1016/j.bbrc.2016.02.061. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2016.02.061)

[7. (Wendler2001Syntaxin) Franz Wendler and Sharon Tooze. Syntaxin 6: the promiscuous behaviour of a snare protein. Traffic, 2(9):606–611, September 2001. URL: http://dx.doi.org/10.1034/j.1600-0854.2001.20903.x, doi:10.1034/j.1600-0854.2001.20903.x. This article has 94 citations and is from a peer-reviewed journal.](https://doi.org/10.1034/j.1600-0854.2001.20903.x)

[8. (Cheng2010Syntaxin) Jie Cheng, Valeriu Cebotaru, Liudmila Cebotaru, and William B. Guggino. Syntaxin 6 and cal mediate the degradation of the cystic fibrosis transmembrane conductance regulator. Molecular Biology of the Cell, 21(7):1178–1187, April 2010. URL: http://dx.doi.org/10.1091/mbc.e09-03-0229, doi:10.1091/mbc.e09-03-0229. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e09-03-0229)